Second allogeneic hematopoietic stem cell transplantation: A treatment for graft failure

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages

  Remberger, Mats ^a   Mattsson, Jonas ^a   Olsson, Richard ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Conditioning; Graft failure; Hematopoietic stem cell transplantation; Rejection

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CHILD; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; INFANT; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; SURVIVAL RATE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; REOPERATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551696034     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01324.x     Document Type: Article

References (63)

1. Blume K, Forman S, Appelbaum F. Thomas' Hematopoietic Cell Transplantation. Oxford: Blackwell Science Ltd, 2004.
2. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program [see comments]. N Engl J Med 1993: 328: 593.
3. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anaemia. An analysis of factors associated with graft rejection. N Engl J Med 1977: 296: 61.
4. Donohue J, Homge M, Kernan NA. Characterization of cells emerging at the time of graft failure after bone marrow transplantation from an unrelated marrow donor. Blood 1993: 82: 1023.
5. Ash RC, Casper JT, Chitambar CR et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990: 322: 485.
6. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989: 320: 197.
7. Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002: 29: 545.
8. Baron F, Maris MB, Storer BE et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005: 11: 272.
9. Davies SM, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000: 96: 4096.
10. Ash RC, Horowitz MM, Gale RP et al. Bone marrow transplantation from related donors other than HLA- identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991: 7: 443.
11. Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. Rev Clin Exp Hematol 2001: 5: 87.
12. Heinzelmann F, Lang PJ, Ottinger H et al. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys 2008: 70: 523.
13. Byrne BJ, Horwitz M, Long GD et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. Bone Marrow Transplant 2008: 41: 39.
14. Lang P, Mueller I, Greil J et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis 2008: 40: 33.
15. Chewning JH, Castro-Malaspina H, Jakubowski A et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007: 13: 1313.
16. Jabbour E, Rondon G, Anderlini P et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 2007: 40: 431.
17. Fernandes J, Rocha V, Robin M et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol 2007: 137: 248.
18. Guardiola P, Kuentz M, Garban F et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000: 111: 292.
19. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998: 16: 2817.
20. Uzunel M, Remberger M, Sairafi D et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006: 82: 913.
21. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997: 89: 3048.
22. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipient with leukemia. Blood 1994: 83: 2723.
23. Remberger M, Svahn B-M, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999: 24: 823.
24. Storb R, Deeg H, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729.
25. Ringdén O, Horowitz M, Sondel P. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993: 18: 1094.
26. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003: 101: 1620.
27. Cutler C, Kim HT, Hochberg E et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004: 10: 328.
28. LeBlanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007: 21: 1733.
29. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995: 15: 619.
30. Svahn BM, Remberger M, Myrback KE et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002: 100: 4317.
31. Ljungman P, Lore K, Aschan J et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996: 17: 583.
32. Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2hours. An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225.
33. Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004: 104: 1923.
34. Lee SJ, Klein J, Haagenson M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007: 110: 4576.
35. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995: 86: 1606.
36. Petersdorf EW, Anasetti C, Martin PJ, Hansen JA. Tissue typing in support of unrelated hematopoietic cell transplantation. Tissue Antigens 2003: 61: 1.
37. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading (11Review) (11 refs). Bone Marrow Transplant 1995: 15: 825.
38. Ringdén O. Management of graft-versus-host disease. Eur J Haematol 1993: 51: 1.
39. Sparrelid E, Hagglund H, Remberger M et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998: 22: 795.
40. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457.
41. Woodard P, Tong X, Richardson S et al. Etiology and outcome of graft failure in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol 2003: 25: 955.
42. Kernan NA, Bordignon C, Heller G et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989: 74: 2227.
43. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003: 102: 2021.
44. Wagner JE, Barker JN, DeFor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002: 100: 1611.
45. Nordlander A, Mattsson J, Sundberg B, Sumitran-Holgersson S. Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation. Transplantation 2008: 86: 686.
46. Grandage VL, Cornish JM, Pamphilon DH et al. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation. Bone Marrow Transplant 1998: 21: 687.
47. Michallet M, Tanguy ML, Socie G et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle. Br J Haematol 2000: 108: 400.
48. Shah AJ, Kapoor N, Weinberg KI et al. Second hematopoietic stem cell transplantation in pediatric patients: overall survival and long-term follow-up. Biol Blood Marrow Transplant 2002: 8: 221.
49. Schlegel PG, Eyrich M, Bader P et al. OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol 2000: 111: 668.
50. Gyurkocza B, Cao TM, Storb RF et al. Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allograft. Biol Blood Marrow Transplant 2009: 15: 1314.
51. Kedmi M, Resnick IB, Dray L et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009: 15: 483.
52. Rondon G, Saliba RM, Khouri I et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008: 14: 859.
53. Davies SM, Weisdorf DJ, Haake RJ et al. Second infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994: 14: 73.
54. Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant 2007: 13: 1249.
55. Parikh SH, Szabolcs P, Prasad VK et al. Correction of chronic granulomatous disease after second unrelated-donor umbilical cord blood transplantation. Pediatr Blood Cancer 2007: 49: 982.
56. Munoz A, Olive T, Martinez A et al. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol 2007: 24: 393.
57. Mugishima H, Ohga S, Ohara A, Kojima S, Fujisawa K, Tsukimoto I. Hematopoietic stem cell transplantation for Diamond-Blackfan anemia: a report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology. Pediatr Transplant 2007: 11: 601.
58. McCann SR, Bacigalupo A, Gluckman E et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994: 13: 233.
59. Al-Qurashi F, Ayas M, Al Sharif F et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology 2004: 9: 123.
60. Ringden O, Svenberg P, Le Blanc K, Mattsson J, Remberger M. Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. Bone Marrow Transplant 2006: 38: 321.
61. Svenberg P, Remberger M, Svennilson J et al. Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. Biol Blood Marrow Transplant 2004: 10: 877.
62. Ringden O, Remberger M, Svenberg P et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. Bone Marrow Transplant 2007: 39: 383.
63. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008: 41: 99.